At­tempt­ing to bounce back af­ter mid-stage flop, Novus piv­ots to im­munol­o­gy with CD40L-fo­cused ac­qui­si­tion of Anelix­is

Fol­low­ing a mid-stage fail­ure of its acute oti­tis me­dia can­di­date back in June that sent its shares deep in­to pen­ny stock ter­ri­to­ry, Novus Ther­a­peu­tics …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.